NCT00772499

Vascular Improvement With Olmesartan Medoxomil Study

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 100 (actual)
• Sponsor: Daiichi Sankyo · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to compare in patients with primary hypertension, the non-blood pressure lowering effects of one-year therapy with olmesartan medoxomil vs. those of atenolol on changes in the vascular structure and function.

Conditions

• Hypertension

Interventions

Type	Name	Description
DRUG	olmesartan medoxomil + hydrochlorothiazide + amlodipine + hydralazine if necessary to control blood pressure	Tablets and capsules for oral administration once or twice daily for up to 52 weeks
DRUG	atenolol+ hydrochlorothiazide + amlodipine + hydralazine if necessary to control blood pressure	Tablets and capsules for oral administration once or twice daily for up to 52 weeks

Timeline

• Start date: 2002-11-01
• Primary completion: 2005-07-01
• Completion: 2005-07-01
• First posted: 2008-10-15
• Last updated: 2008-10-15

Locations

1 site across 1 country: United States